Basel, January 27, 2014 – Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100.Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World (Global 100) index to…
Copenhagen, January 20, 2014 – Sandoz announces that it is launching in Denmark today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).The product was first approved in Denmark…
Holzkirchen, Germany, January 16, 2014 – Sandoz announced it has received marketing authorization in Hungary for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.The product was first approved in Denmark on December 18t…
Holzkirchen, Germany, January 14, 2014 – Sandoz announced today it has received Swedish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.The product was first approved in Denmark on December …
Holzkirchen, Germany, January 13, 2014 – Sandoz announced today it has received German marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.The product was first approved in Denmark on December 1…
Januar 08, 2014 – Novartis recently published a comprehensive overview of its Corporate Responsibility strategy and programs.Learn more (PDF 743 KB)
Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the USBiosimilar filgrastim recommended to be approved for use in all requested indicationsCommittee’s recommendation based on review of exte…
Munich, December 18, 2013 – Sandoz announced today that it has received Danish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The Danish approval…